companies developing glp-1 drugs Market Size to Hit USD 132.79 Bn by 2035 It Is a Huge Market.
Description
Centers for Disease Control and Prevention
Clinical guidelines are expanding to recommend GLP-1 therapies for this group, supported by evidence showing effective weight loss and metabolic benefits at this stage
Phase 2 and 3 studies, such as randomized controlled trials, have shown that these agents significantly reduce liver fat content, improve liver enzyme profiles, and promote histological improvements in patients with MASLD and MASH (6, 46)
Biofactors 44, 148157
Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity [Internet]
